C
Christine Huynh
Researcher at University of Basel
Publications - 6
Citations - 64
Christine Huynh is an academic researcher from University of Basel. The author has contributed to research in topics: Pharmacokinetics & Medicine. The author has an hindex of 3, co-authored 4 publications receiving 21 citations.
Papers
More filters
Journal ArticleDOI
Relevance of the CXCR4/CXCR7-CXCL12 axis and its effect in pathophysiological conditions
TL;DR: An overview is presented of the most important diseases whose outcomes can be positively or negatively regulated by the CXCR4/CXCR7-CXCL12 axis and summarizes preclinical and clinical data of modulators of that axis.
Journal ArticleDOI
Absorption, distribution, metabolism and excretion of the P2Y12 receptor antagonist selatogrel after subcutaneous administration in healthy subjects.
TL;DR: Overall, none of the metabolic pathways contributed to a relevant extent to the overall elimination of selatogrel, i.e. by more than 25% as defined per regulatory guidance, and no pharmacokinetic interaction studies with inhibitors or inducers of drug-metabolizing enzymes are warranted for clinical development of se latogrel.
Journal ArticleDOI
A Multipurpose First-in-Human Study With the Novel CXCR7 Antagonist ACT-1004-1239 Using CXCL12 Plasma Concentrations as Target Engagement Biomarker.
Christine Huynh,Andrea Henrich,Daniel S. Strasser,Marie-Laure Boof,Mohamed Al-Ibrahim,Henriette E. Meyer zu Schwabedissen,Jasper Dingemanse,Mike Ufer +7 more
TL;DR: ACT-1004-1239 as mentioned in this paper is a drug candidate small-molecule CXCR7 antagonist that has been shown to be safe and well tolerated up to the highest tested dose of 200 mg.
Journal ArticleDOI
Target engagement of the first-in-class CXCR7 antagonist ACT-1004-1239 following multiple-dose administration in mice and humans.
Christine Huynh,Janneke M. Brussee,Laetitia Pouzol,Marlene Fonseca,Henriette E. Meyer zu Schwabedissen,Jasper Dingemanse,Patricia N. Sidharta +6 more
TL;DR: In this paper, the first-in-class CXCR7 antagonist, ACT-1004-1239, showed efficacy in animal models of multiple sclerosis and acute lung injury.
Journal ArticleDOI
Absorption, Metabolism, and Excretion of ACT-1004-1239, a First-In-Class CXCR7 Antagonist: In Vitro, Preclinical, and Clinical Data
Christine Huynh,Swen Seeland,Jérôme Segrestaa,Carmela Gnerre,Jens Hogeback,Henriette E. Meyer zu Schwabedissen,Jasper Dingemanse,Patricia N. Sidharta +7 more
TL;DR: In conclusion, CYP3A4 contributes to a relevant extent to ACT-1004-1239 disposition and two major circulating metabolites were observed in humans.